RSV Prevention Tied to Lower Infant Acute Care Use - Summary - MDSpire

RSV Prevention Tied to Lower Infant Acute Care Use

  • By

  • Andrea Surnit

  • May 5, 2026

  • 5 min

Share

Objective:

To assess the impact of nirsevimab and maternal RSV vaccination on respiratory syncytial virus-associated hospitalizations and emergency department visits among infants aged 7 months or younger.

Key Findings:
  • 43% relative decrease in RSV-associated hospitalizations and emergency department visits among infants aged 7 months or younger during the second year of nirsevimab and maternal vaccination, with statistical significance.
  • Estimated population impact varied across counties, ranging from 15.5% to 57.7%, indicating varying effectiveness.
  • Median age of RSV cases increased from 9 months to 12 months, indicating a shift in disease burden.
Interpretation:

The findings suggest that population-level interventions like nirsevimab and maternal vaccination significantly reduce RSV-related acute care use among infants.

Limitations:
  • Reliance on diagnosis codes rather than laboratory confirmation may lead to misclassification.
  • Race and ethnicity data extraction methods were unclear, with unknown race for 11% of cases.
  • The ecological design limits causal interpretation due to lack of individual-level data.
  • The comparison group may have included some children eligible for nirsevimab, affecting the validity of the findings.
Conclusion:

The study highlights the effectiveness of RSV prevention strategies in reducing hospitalizations and emergency visits among infants, with significant implications for future public health recommendations.

Original Source(s)

Related Content